Drug application
DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE (ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE)
Drugs@FDA ANDA 210811 · CIPLA LIMITED
Key facts
| Drug name | DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE |
|---|---|
| Active ingredients | ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE |
| Application type | ANDA |
| Application number | 210811 |
| Company | CIPLA LIMITED |
| Dosage forms | TABLET |
| Strength | 300MG |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission status date | Jun 12, 2025 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.